title: Servier's pipeline in oncology: moving from research to patients.
authors.affiliation: Oncology PIT, IRIS, 50 Rue Carnot, 92284, Suresnes, France.
authors.forename: Patrick
authors.initials: P
authors.lastname: Therasse
authors.affiliation: Oncology PIT, IRIS, 50 Rue Carnot, 92284, Suresnes, France.
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Abastado
mesh_terms: D000911:Antibodies, Monoclonal / Q000187:drug effects / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D064987:Cell- and Tissue-Based Therapy / Q000379:methods; D017326:Clinical Trials, Phase III as Topic; D003131:Combined Modality Therapy; D055808:Drug Discovery; D004345:Drug Industry / Q000458:organization & administration*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007546:Isoquinolines / Q000494:pharmacology / Q000627:therapeutic use; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000473:pathology; D008495:Medical Oncology; D009369:Neoplasms / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D057285:Precision Medicine; D015202:Protein Engineering; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D055818:Public-Private Sector Partnerships; D059005:Topoisomerase II Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D057170:Translational Research, Biomedical
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D007546:Isoquinolines; D047428:Protein Kinase Inhibitors; D059005:Topoisomerase II Inhibitors; C086548:pixantrone
keywords: Servier; hematology; research pipeline; solid tumors